[go: up one dir, main page]

CL2012002362A1 - Sales cristalinas de trometamina y de colina de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; composicion farmaceutica que las comprende, utiles para el tratamiento de la infeccion por el virus de la hepatitis c. - Google Patents

Sales cristalinas de trometamina y de colina de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; composicion farmaceutica que las comprende, utiles para el tratamiento de la infeccion por el virus de la hepatitis c.

Info

Publication number
CL2012002362A1
CL2012002362A1 CL2012002362A CL2012002362A CL2012002362A1 CL 2012002362 A1 CL2012002362 A1 CL 2012002362A1 CL 2012002362 A CL2012002362 A CL 2012002362A CL 2012002362 A CL2012002362 A CL 2012002362A CL 2012002362 A1 CL2012002362 A1 CL 2012002362A1
Authority
CL
Chile
Prior art keywords
tromethamine
quinolinyl
choline
thiazolyl
oxy
Prior art date
Application number
CL2012002362A
Other languages
English (en)
Inventor
Ka Yin
Bing Shiou Yang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43778392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002362(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2012002362A1 publication Critical patent/CL2012002362A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Sales cristalinas de trometamina, colina y n-metil-d-glucamina de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; composición farmacéutica que las comprende, útil para el tratamiento de la infección por el virus de la hepatits C.
CL2012002362A 2010-03-11 2012-08-24 Sales cristalinas de trometamina y de colina de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; composicion farmaceutica que las comprende, utiles para el tratamiento de la infeccion por el virus de la hepatitis c. CL2012002362A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31279110P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
CL2012002362A1 true CL2012002362A1 (es) 2013-01-11

Family

ID=43778392

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002362A CL2012002362A1 (es) 2010-03-11 2012-08-24 Sales cristalinas de trometamina y de colina de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; composicion farmaceutica que las comprende, utiles para el tratamiento de la infeccion por el virus de la hepatitis c.

Country Status (18)

Country Link
US (3) US8530497B2 (es)
EP (1) EP2545049B1 (es)
JP (2) JP5687291B2 (es)
KR (1) KR101756632B1 (es)
CN (2) CN102844315B (es)
AR (1) AR080494A1 (es)
AU (1) AU2011224311B2 (es)
BR (1) BR112012022812A2 (es)
CA (1) CA2792684C (es)
CL (1) CL2012002362A1 (es)
EA (1) EA021805B1 (es)
IL (1) IL221198A (es)
MX (1) MX2012009964A (es)
NZ (1) NZ601563A (es)
PH (1) PH12012501805A1 (es)
TW (1) TW201200511A (es)
UY (1) UY33270A (es)
WO (1) WO2011112761A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140666T1 (hr) * 2008-09-16 2014-10-10 Boehringer Ingelheim International Gmbh Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora
WO2010033443A1 (en) 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
ES2735355T3 (es) 2013-03-15 2019-12-18 Gilead Sciences Inc Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US10927067B2 (en) * 2016-11-28 2021-02-23 Sarin Parayil Organic crystalline salt of haloacetic acid
WO2024237331A1 (ja) * 2023-05-17 2024-11-21 オンコリスバイオファーマ株式会社 フェナントリジノン誘導体のコリン塩

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2308955T5 (es) 1993-09-28 2012-04-03 R.P. Scherer Gmbh Fabricación de cápsulas de gelatina blanda
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
DE602004010137T2 (de) * 2003-05-21 2008-09-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbindungen als hepatitis c inhibitoren
JP5156374B2 (ja) * 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非環式ｈｃｖプロテアーゼインヒビターの調製方法
HRP20140666T1 (hr) 2008-09-16 2014-10-10 Boehringer Ingelheim International Gmbh Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor

Also Published As

Publication number Publication date
CN104945396B (zh) 2018-02-27
CN102844315A (zh) 2012-12-26
EP2545049B1 (en) 2015-10-14
PH12012501805A1 (en) 2022-10-05
MX2012009964A (es) 2012-09-21
KR20130009966A (ko) 2013-01-24
CA2792684A1 (en) 2011-09-15
NZ601563A (en) 2013-12-20
IL221198A (en) 2017-01-31
US9382240B2 (en) 2016-07-05
UY33270A (es) 2011-10-31
BR112012022812A2 (pt) 2018-05-15
TW201200511A (en) 2012-01-01
IL221198A0 (en) 2012-10-31
CN102844315B (zh) 2015-05-20
EA021805B1 (ru) 2015-09-30
AU2011224311B2 (en) 2014-08-14
AR080494A1 (es) 2012-04-11
CA2792684C (en) 2018-07-31
JP2013522221A (ja) 2013-06-13
AU2011224311A1 (en) 2012-08-23
JP2015143223A (ja) 2015-08-06
US20150166530A1 (en) 2015-06-18
US20130317061A1 (en) 2013-11-28
US20120059033A1 (en) 2012-03-08
KR101756632B1 (ko) 2017-07-11
EP2545049A1 (en) 2013-01-16
WO2011112761A1 (en) 2011-09-15
US8530497B2 (en) 2013-09-10
EA201201277A1 (ru) 2013-04-30
JP5687291B2 (ja) 2015-03-18
CN104945396A (zh) 2015-09-30

Similar Documents

Publication Publication Date Title
CL2012002362A1 (es) Sales cristalinas de trometamina y de colina de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; composicion farmaceutica que las comprende, utiles para el tratamiento de la infeccion por el virus de la hepatitis c.
UY35362A (es) Compuestos terapéuticos
UY35263A (es) Compuestos terapéuticos
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
MX2017009244A (es) Compuestos de pirazina novedosos para el tratamiento de enfermedades infecciosas.
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
CO6561783A2 (es) Inhibidores del virus flaviviridae
CO7160104A2 (es) Inhibidores de virus de hepatitis c
CO6801646A2 (es) Eliminación de células diana por parte de células t citotóxicas específicas de virus utilizando complejos que comprenden mhc de clase i
ECSP13013040A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
CL2013001428A1 (es) Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
ECSP12012104A (es) Inhibidores de virus flaviviridae
CL2015000487A1 (es) Compuestos derivados de sulfamoilarilamidas; composicion farmaceutica que los comprende, util para la prevencion o tratamiento de una infeccion por el virus de la hepatitis b (vhb).
ECSP14013199A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
UY33897A (es) Inhibidores del virus de la hepatitis c
CO7240410A2 (es) Inhibidores macrocíclicos de virus flaviviridae
CL2014000393A1 (es) Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion.
CR20130054A (es) Procesos para preparar compuestos antivirales
UY34066A (es) Inhibidores del virus de la hepatitis c
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
CL2014000394A1 (es) Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo